Member Info for DeAar

I'll buy when it gets to 100p.

30% down since the RF funding announcement (2.5 months ago). No big news is expected till somewhere in H1 24. Who knows where this will bottom out.

Why don't you just register and ask the questions yourself Ahfam? For someone who's life seems to revolve around this share, one would think you'd be all over it.

Thinking back to the AGM, you were on here asking what was happening when you could have just registered and watched it online. Very strange behaviour indeed.

Dracula,

The SP opened at 9.34 on the 15th Sept and reached a high of 18.30 on the 20th Sept. That's pretty much a 100% climb. Currently sitting at 15.15 which is about 60% up from the 15th September opening. The SP has therefore a decent lift and held most of it.

No hasiba, they give short lived SP boosts which day traders like yourself make money off. You don't give a rats @ss about anything else!

Hasiba,

In the RNS on the 10th July under the heading "Antibody Platform", the following was written - "The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company."

This was before the SP went to 8p. I don't think the BOD would be allowed to buy shares while they were actively engaging with other companies. And in the last RNS, they mentioned potential deals with three companies...

Ahfam,

I appreciate your civil response.

The daily chart looks awful. Like a slinky spring going down a staircase. It looks like its heading for the next lower step or two this week.

You're trying way to hard to ramp this. It's really not needed.

I notice the tweet was at 7:03 on Friday morning. As WTP picked up, Friday was a relatively large volume day for Scancell, along with a 6% SP increase.

From a Korean oncology market analyst on Friday.

https://twitter.com/onco_park/status/1702563786690068832?t=e7tfdaQmXXW_6tC331meUw&s=19

Could this have something to do with this morning's SP movement?

Need a lot of cardboard for them all!

Ahfam,

The RNS's on the 6th June, 3rd and 16th August 2023 all say that the full data readout for the p1a trial will be in H1 2024. That's really inconvenient for your ramping isn't it?

Till end Jan 24. Two Director dealing RNS"s this week and the SP hardly budged. Where will the SP be in January before the expected P1 trial data? That's when the next expected news is folks. Maybe down at the fabled 28p?

Ahfam,

In the land of the rich, you are poverty stricken. You're on here all day "protecting" your 39000 shares. You need to sell some to pay off bills from time to time. I doubt you have the £20000 to fill your annual ISA allowance.

Tell us about Scancell Ahananda?

The LTH's here seem like such nice people. They hope others will be financially ruined, lose everything, resort to name calling and insults and even try get posters banned if they don't like their opinion.

PUMA has stated what he intended to do, and why, straight after the Riverfort financing was RNS'd. He has given price levels and and justification. He has not laughed at or insulted anyone. And yet there is all this vitriol...

Lay the blame where it belongs - the BOD. They decided on the Riverfort financing and this share slide is the direct result of their actions.

Ahfam - In your post at 18:46 you state:

"- so with that in mind take advantage of the low price because most are."

Is that financial advice? Can you prove it?

It seems like the kitty has been doxed on the other BB.

From the 6th June RNS - "The phase 1a trial includes a single ascending dose study (Part 1), a multiple ascending dose study (Part 2) and a food effects study (Part 3). Part 1 will consist of at least 6 sequential, ascending dose cohorts of 8 subjects each (total of 48 subjects) randomised to receive SDC-1801 or matched placebo in a 3:1 ratio. Each subject will be in Part 1 for approximately 6 weeks (screening visit to follow-up visit). Part 2 (multiple ascending dose) is planned to commence after the Safety Review Committee (SRC) has evaluated the available data from at least Cohorts A, B, and C in Part 1.

The multiple ascending dose part of the trial will consist of at least 4 sequential, ascending doses of SDC-1801 or matched placebo cohorts (cohorts A to D). Each cohort in Part 2 will consist of 8 subjects (a total of 32 subjects). Each subject will be in the study for approximately 8 weeks. Part 3 of the study is expected to run in parallel with Part 2, and will examine how food affects the absorption of SDC-1801.

The Company expects to provide a further update on the trial once initial safety and pharmacokinetic data observed in the single ascending dose study provide sufficient support for progression to Part 2 of the study, expected in H2 2023."

The full safety data for the above P1a trial is expected to be available in H1 2024. The P1b trial for psoriasis will start shortly after.